drugset / Trial / NCT01623908

Bone Loss Treatment From Adjuvant Zoledronate Efficacy

NCT01623908

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to observe and assess the impact of adjuvant zoledronate on bone density in breast cancer patients. The second purposes: * The efficacy of adjuvant zoledronate * The safety of adjuvant zoledronate * The bone loss of breast cancer patients in Guangdong * The correlation between bone loss of breast cancer patients and treatment of disease in Guangdong

Timeline

Start
2011-07
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronate Other / unclassified 4 mg Intravenous